Novo Nordisk stock last at EUR 34.015 in Xetra trading
Published on 09/25/2026 at 18:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk was last at EUR 34.015 on Xetra at 3:06 p.m. CET on September 25, 2026, up 0.99 percent and EUR 0.335 from the prior reference. The stock outperformed the OMX Copenhagen 20, which fell 0.01 percent during the session. The Nanexa agreement provided the day's most significant company development.
The session on September 25, 2026 in figures
Novo Nordisk A/S (ISIN DK0062498333, Xetra: NOV) was last at EUR 34.015 on Xetra at 3:06 p.m. CET. The move represented a gain of EUR 0.335, or 0.99 percent, against the EUR 33.680 reference from September 24, 2026. The Xetra value was an intraday level rather than an official end-of-session value.
The earlier Xetra session showed Novo Nordisk at EUR 33.870 at 11:20 a.m. CET, up 0.56 percent and EUR 0.190. The stock therefore added EUR 0.145 between 11:20 a.m. CET and 3:06 p.m. CET. The later level stood 1.00 percentage point above the OMX Copenhagen 20 performance.
Nanexa deal and analyst target cuts shape the background
The Nanexa agreement gave Novo Nordisk access to Pharmashell drug-delivery technology in up to five development programs. As Finanznachrichten reported on September 25, 2026, the arrangement carried potential payments of up to EUR 1.2 billion. The agreement included EUR 615 million in upfront payments plus development and regulatory milestones. Novo Nordisk will lead worldwide development and commercialization.
Deutsche Bank Research kept its Sell rating and reduced its target from DKK 265 to DKK 245 after the capital markets day. As dpa-AFX reported on September 22, 2026, analyst Emmanuel Papadakis said earlier optimistic expectations had been disappointed on several fronts. Jefferies reiterated Hold and cut its target from DKK 285 to DKK 275, citing patent-expiry uncertainty and a premium valuation.
Copenhagen market and life-science comparisons on September 25, 2026
The OMX Copenhagen 20 fell 0.01 percent and reached a new three-month low, according to Investing.com on September 25, 2026. The report said healthcare, oil and gas, and personal and household goods led the weaker groups. Novozymes fell 4.20 percent to DKK 424.30, while DSV rose 2.12 percent to DKK 1,207.00. Nanexa, the licensing partner, rose 111.70 percent in the related Stockholm session.
